

Active substances set

Search phrase: tremelimumab

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Liver cancer

Tremelimumab

Tremelimumab in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).



**FULL
REIMBURSEMENT**



ESMO

Tracheal, bronchus, and lung cancer

Tremelimumab

Tremelimumab in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.



NO REIMBURSEMENT



ESMO